Adient (ADNT) Misses Q3 EPS by 31c, lowers guidance

Adient (NYSE: ADNT) reported Q3 EPS of $0.32, $0.31 worse than the analyst estimate of $0.63. Revenue for the quarter came in at $3.72 billion versus the consensus estimate of $3.83 billion.

Guidance: FY 2024:

Consolidated Sales: $14.6 billion, versus the consensus of $14.8 billion and prior guidance of $14.8 to $14.9 billion

For earnings history and earnings-related data on Adient (ADNT) click here.

You May Also Be Interested In

• Evercore ISI Starts Credo Tech (CRDO) at Outperform
• H.C. Wainwright Starts Faeth Therapeutics (FTH) at Buy
• Micron Technology (MU) call put ratio 1 calls to 1.1 puts into quarter results